4 November 2025, Paris, France. Opella today announced that the Science Based Targets initiative (SBTi) has officially validated its near-and long-term emissions reduction targets. This key milestone confirms Opella’s climate strategy is aligned with the global +1.5°C pathway and the Paris Agreement and commits Opella to reach net-zero carbon emissions across its operations and value chain by 2050.

The SBTi is a partnership between the Carbon Disclosure Project (CDP), the United Nations Global Compact (UNGC), the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). This validation recognizes Opella’s targets as aligned with the corporate net-zero standard, the world’s first and only framework for corporate net-zero target setting in line with climate science.

Opella is the first pure-play global consumer healthcare company to have obtained both B Corp certification and to have its net-zero commitments approved by SBTi, reflecting a deep commitment to combining scientific rigor with social and environmental accountability.

Julie Van Ongevalle, Opella President & Chief Executive Officer.
Being both B Corp certified and SBTi validated shows just how committed we are to transforming our business in ways that protect both human and planetary health. I am proud to lead a courageaous team driving meaningful change.

Marissa Saretsky, Chief Sustainability Officer at Opella.
Science is our compass and data is our roadmap. The SBTi‘s validation confirms that our climate strategy is built on evidence and we are accountable to follow through. Decarbonizing our business is essential for long-term resilience and impact and we are proud to be part of a global movement that is turning ambition into action.

From a 2023 baseline, Opella commits to a -58.8% reduction in carbon emissions across Scopes 1, 2, and 3 by 2034. The company further commits to a -90% absolute reduction by 2050. These targets address carbon emissions across both the company’s operations and value chain, and deep decarbonization efforts will be prioritized over offset reliance.

Achieving these goals will require transforming Opella’s how Opella does business, including sourcing lowcarbon raw materials, redesigning packaging, shifting to 100% renewable electricity, and partnering with suppliers to meet their own science-based targets. Opella will report on its progress annually and review its climate targets regularly to ensure continued alignment with evolving climate science.

About Opella.
Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet.

Find out more about our mission at www.opella.com.

Press Contact.
Justine Rohée. justine.rohee@sanofi.com. +33 6 86 47 85 60.
Natacha Kalasa. natacha.kalasa@sanofi.com. +33 6 72 16 64 61.